Boston Scientific ROE 2010-2024 | BSX
Current and historical return on equity (ROE) values for Boston Scientific (BSX) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Boston Scientific ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2024-09-30 | $1.79B | $20.96B | 8.82% |
| 2024-06-30 | $1.83B | $20.61B | 9.20% |
| 2024-03-31 | $1.77B | $20.17B | 9.13% |
| 2023-12-31 | $1.57B | $19.53B | 8.35% |
| 2023-09-30 | $1.19B | $19.13B | 6.50% |
| 2023-06-30 | $0.86B | $18.49B | 4.79% |
| 2023-03-31 | $0.85B | $18.11B | 4.79% |
| 2022-12-31 | $0.64B | $17.57B | 3.71% |
| 2022-09-30 | $0.60B | $17.64B | 3.50% |
| 2022-06-30 | $0.83B | $17.25B | 4.94% |
| 2022-03-31 | $0.76B | $16.74B | 4.59% |
| 2021-12-31 | $0.99B | $16.62B | 6.09% |
| 2021-09-30 | $1.10B | $16.46B | 6.93% |
| 2021-06-30 | $0.53B | $15.94B | 3.36% |
| 2021-03-31 | $0.20B | $15.72B | 1.29% |
| 2020-12-31 | $-0.12B | $15.33B | -0.76% |
| 2020-09-30 | $3.69B | $15.56B | 25.04% |
| 2020-06-30 | $3.98B | $15.62B | 30.04% |
| 2020-03-31 | $4.29B | $13.80B | 36.64% |
| 2019-12-31 | $4.70B | $13.88B | 44.51% |
| 2019-09-30 | $1.09B | $9.70B | 11.76% |
| 2019-06-30 | $1.40B | $9.43B | 15.65% |
| 2019-03-31 | $1.80B | $9.23B | 21.15% |
| 2018-12-31 | $1.67B | $8.73B | 21.03% |
| 2018-09-30 | $0.67B | $8.29B | 8.91% |
| 2018-06-30 | $0.52B | $7.74B | 7.09% |
| 2018-03-31 | $0.11B | $7.03B | 1.55% |
| 2017-12-31 | $0.10B | $7.01B | 1.44% |
| 2017-09-30 | $0.84B | $7.59B | 11.79% |
| 2017-06-30 | $0.79B | $7.24B | 11.46% |
| 2017-03-31 | $0.44B | $7.05B | 6.57% |
| 2016-12-31 | $0.35B | $6.73B | 5.36% |
| 2016-09-30 | $0.08B | $6.48B | 1.27% |
| 2016-06-30 | $-0.35B | $6.22B | -5.43% |
| 2016-03-31 | $-0.04B | $6.46B | -0.56% |
| 2015-12-31 | $-0.24B | $6.32B | -3.70% |
| 2015-09-30 | $-0.40B | $6.41B | -6.10% |
| 2015-06-30 | $-0.16B | $6.58B | -2.36% |
| 2015-03-31 | $-0.25B | $6.50B | -3.86% |
| 2014-12-31 | $-0.12B | $6.46B | -1.81% |
| 2014-09-30 | $0.29B | $6.70B | 4.38% |
| 2014-06-30 | $0.24B | $6.54B | 3.67% |
| 2014-03-31 | $0.37B | $6.53B | 5.58% |
| 2013-12-31 | $-0.12B | $6.54B | -1.85% |
| 2013-09-30 | $-0.17B | $6.56B | -2.53% |
| 2013-06-30 | $-0.83B | $6.60B | -12.34% |
| 2013-03-31 | $-4.54B | $6.50B | -64.95% |
| 2012-12-31 | $-4.07B | $6.87B | -49.58% |
| 2012-09-30 | $-4.02B | $6.83B | -43.13% |
| 2012-06-30 | $-3.22B | $7.73B | -30.63% |
| 2012-03-31 | $0.51B | $11.40B | 4.44% |
| 2011-12-31 | $0.44B | $11.35B | 3.85% |
| 2011-09-30 | $0.57B | $11.52B | 4.99% |
| 2011-06-30 | $0.62B | $11.54B | 5.46% |
| 2011-03-31 | $0.57B | $11.37B | 5.11% |
| 2010-12-31 | $-1.07B | $11.30B | -9.68% |
| 2010-09-30 | $-2.38B | $11.04B | -21.12% |
| 2010-06-30 | $-2.66B | $10.89B | -22.52% |
| 2010-03-31 | $-2.60B | $10.78B | -20.89% |
| 2009-12-31 | $-1.03B | $12.30B | -7.84% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $133.131B | $14.240B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $203.157B | 25.91 |
| Stryker (SYK) | United States | $148.171B | 33.39 |
| EssilorLuxottica (ESLOY) | France | $113.461B | 0.00 |
| Medtronic (MDT) | Ireland | $109.010B | 16.19 |
| Haleon (HLN) | United Kingdom | $42.913B | 27.88 |
| Lonza Group Ag (LZAGY) | Switzerland | $42.122B | 0.00 |
| GE HealthCare Technologies (GEHC) | United States | $37.701B | 19.56 |
| ResMed (RMD) | United States | $34.955B | 28.72 |
| Terumo (TRUMY) | Japan | $29.203B | 41.24 |
| Koninklijke Philips (PHG) | Netherlands | $24.410B | 18.68 |
| Zimmer Biomet Holdings (ZBH) | United States | $22.087B | 14.06 |
| Insulet (PODD) | United States | $18.377B | 73.18 |
| Baxter (BAX) | United States | $16.604B | 10.80 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $11.153B | 0.00 |
| BellRing Brands (BRBR) | United States | $9.468B | 37.96 |
| Bio-Rad Laboratories (BIO) | United States | $8.977B | 30.51 |
| Demant (WILYY) | Denmark | $8.342B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $5.523B | 12.83 |
| TG Therapeutics (TGTX) | United States | $4.720B | 0.00 |
| Haemonetics (HAE) | United States | $4.260B | 20.79 |
| ICU Medical (ICUI) | United States | $4.155B | 39.56 |
| Prestige Consumer Healthcare (PBH) | United States | $4.074B | 20.26 |
| Perrigo (PRGO) | Ireland | $3.716B | 10.94 |
| Envista Holdings (NVST) | United States | $3.487B | 25.97 |
| Neogen (NEOG) | United States | $3.270B | 37.72 |
| Agios Pharmaceuticals (AGIO) | United States | $3.103B | 0.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| GN Store Nord (GNNDY) | Denmark | $2.789B | 17.89 |
| QuidelOrtho (QDEL) | United States | $2.595B | 16.70 |
| Warby Parker (WRBY) | United States | $2.344B | 0.00 |
| LeMaitre Vascular (LMAT) | United States | $2.332B | 56.69 |
| Green Thumb Industries (GTBIF) | United States | $1.964B | 34.37 |
| AtriCure (ATRC) | United States | $1.772B | 0.00 |
| InMode (INMD) | Israel | $1.487B | 8.94 |
| Curaleaf Holdings (CURLF) | Canada | $1.348B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.311B | 9.37 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.168B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.041B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.962B | 16.96 |
| Owens & Minor (OMI) | United States | $0.957B | 7.48 |
| CeriBell (CBLL) | United States | $0.916B | 0.00 |
| National Vision Holdings (EYE) | United States | $0.888B | 29.68 |
| Capricor Therapeutics (CAPR) | United States | $0.839B | 0.00 |
| Evolus (EOLS) | United States | $0.785B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.608B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.596B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.596B | 26.47 |
| Surmodics (SRDX) | United States | $0.559B | 0.00 |
| Quanterix (QTRX) | United States | $0.424B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.404B | 0.00 |
| Valneva SE (VALN) | France | $0.370B | 0.00 |
| ZimVie (ZIMV) | United States | $0.363B | 30.63 |
| Omeros (OMER) | United States | $0.349B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.335B | 31.89 |
| Biote (BTMD) | United States | $0.330B | 7.25 |
| Sanara MedTech (SMTI) | United States | $0.323B | 0.00 |
| Cerus (CERS) | United States | $0.312B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.288B | 19.30 |
| Zynex (ZYXI) | United States | $0.249B | 52.13 |
| TerrAscend (TSNDF) | Canada | $0.243B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.229B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.219B | 15.15 |
| MacroGenics (MGNX) | United States | $0.218B | 0.00 |
| High Tide (HITI) | Canada | $0.215B | 89.00 |
| Sanuwave Health (SNWV) | United States | $0.195B | 2.74 |
| Jin Medical (ZJYL) | China | $0.188B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.162B | 0.00 |
| Brainsway (BWAY) | Israel | $0.161B | 96.70 |
| Organigram Holdings (OGI) | Canada | $0.158B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.143B | 17.98 |
| TriSalus Life Sciences (TLSI) | United States | $0.126B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.106B | 0.00 |
| Fonar (FONR) | United States | $0.093B | 10.54 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.093B | 23.00 |
| Veru (VERU) | United States | $0.092B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.082B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.080B | 41.50 |
| Modular Medical (MODD) | United States | $0.073B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.070B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.066B | 0.00 |
| InterCure (INCR) | Israel | $0.063B | 0.00 |
| Exagen (XGN) | United States | $0.062B | 0.00 |
| MariMed (MRMD) | United States | $0.059B | 0.00 |
| Safety Shot (SHOT) | United States | $0.056B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.052B | 0.00 |
| Apyx Medical (APYX) | United States | $0.048B | 0.00 |
| ImmuCell (ICCC) | United States | $0.032B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.026B | 0.00 |
| Flora Growth (FLGC) | United States | $0.018B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.011B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Agape ATP (ATPC) | $0.006B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.001B | 0.00 |
| Senestech (SNES) | United States | $0.001B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 13.17 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |